Models of intrahepatic cholangiocarcinoma: novel tools and therapeutic applications

References

• Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13(5):261–280.
   PubMed Web of Science ®Google Scholar
• Liu Y, Meyer C, Xu C, et al. Animal models of chronic liver diseases. Am J Physiol Gastrointest Liver Physiol. 2013;304(5):G449–G468.
   Web of Science ®Google Scholar
• De Minicis S, Kisseleva T, Francis H, et al. Liver carcinogenesis: rodent models of hepatocarcinoma and cholangiocarcinoma. Dig Liver Dis. 2013;45(6):450–459.
   PubMedGoogle Scholar
• Nakagawa H, Hikiba Y, Hirata Y, et al. Loss of liver E-cadherin induces sclerosing cholangitis and promotes carcinogenesis. Proc Natl Acad Sci U S A. 2014;111(3):1090–1095.
   PubMed Web of Science ®Google Scholar
• Moriconi F, Ramadori P, Schultze FC, et al. Characterization of the erythropoietin/erythropoietin receptor axis in a rat model of liver damage and cholangiocarcinoma development. Histochem Cell Biol. 2013;139(3):473–485.
   Web of Science ®Google Scholar
• Heindryckx F, Bogaerts E, Coulon SH, et al. Inhibition of the placental growth factor decreases burden of cholangiocarcinoma and hepatocellular carcinoma in a transgenic mouse model. Eur J Gastroenterol Hepatol. 2012;24(9):1020–1032.
   Web of Science ®Google Scholar
• Yang H, Li TW, Peng J, et al. A mouse model of cholestasis-associated cholangiocarcinoma and transcription factors involved in progression. Gastroenterology. 2011;141(1):378–88, 388.e1–4.
   PubMed Web of Science ®Google Scholar
• Sudsarn P, Boonmars T, Ruangjirachuporn W, et al. Combination of praziquantel and aspirin minimizes liver pathology of hamster Opisthorchis viverrini infection associated cholangiocarcinoma. Pathol Oncol Res. 2016;22(1):57–65.
   Web of Science ®Google Scholar
• Yothaisong S, Thanee M, Namwat N, et al. Opisthorchis viverrini infection activates the PI3K/AKT/PTEN and Wnt/beta-catenin signaling pathways in a Cholangiocarcinogenesis model. Asian Pac J Cancer Prev. 2014;15(23):10463–10468.
   Google Scholar
• Wonkchalee N, Boonmars T, Laummaunwai P, et al. A combination of praziquantel and the traditional medicinal plant Thunbergia laurifolia on Opisthorchis viverrini infection and cholangiocarcinoma in a hamster model. Parasitol Res. 2013;112(12):4211–4219.
   Web of Science ®Google Scholar
• Laothong U, Pinlaor P, Boonsiri P, et al. Melatonin inhibits cholangiocarcinoma and reduces liver injury in Opisthorchis viverrini-infected and N-nitrosodimethylamine-treated hamsters. J Pineal Res. 2013;55(3):257–266.
   Web of Science ®Google Scholar
• Chusorn P, Namwat N, Loilome W, et al. Overexpression of microRNA-21 regulating PDCD4 during tumorigenesis of liver fluke-associated cholangiocarcinoma contributes to tumor growth and metastasis. Tumour Biol. 2013;34(3):1579–1588.
   PubMedGoogle Scholar
• Lee J-H, Rim H-J, Sell S. Heterogeneity of the “oval-cell” response in the hamster liver during cholangiocarcinogenesis following Clonorchis sinensis infection and dimethylnitrosamine treatment. J Hepatol. 1997;26(6):1313–1323.
   Web of Science ®Google Scholar
• Mu X, Pradere J-P, Affò S, et al. Epithelial transforming growth factor-β signaling does not contribute to liver fibrosis but protects mice from cholangiocarcinoma. Gastroenterology. 2016;150(3):720–733.
   Web of Science ®Google Scholar
• Li J, Razumilava N, Gores GJ, et al. Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest. 2014;124(7):3241–3251.
   PubMed Web of Science ®Google Scholar
• Sekiya S, Suzuki A. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. J Clin Invest. 2012;122(11):3914–3918.
   PubMed Web of Science ®Google Scholar
• Guest RV, Boulter L, Kendall TJ, et al. Cell lineage tracing reveals a biliary origin of intrahepatic cholangiocarcinoma. Cancer Res. 2014;74(4):1005–1010.
   PubMed Web of Science ®Google Scholar
• Thamavit W, Bhamarapravati N, Sahaphong S, Vajrasthira S, Angsubhakorn S. Effects of dimethylnitrosamine on induction of cholangiocarcinoma in Opisthorchis viverrini-infected Syrian golden hamsters. Cancer Res. 1978;38(12):4634–4639.
   Web of Science ®Google Scholar
• Farazi PA, Zeisberg M, Glickman J, Zhang Y, Kalluri R, DePinho RA. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res. 2006;66(13):6622–6627.
   Web of Science ®Google Scholar
• Saha SK, Parachoniak CA, Ghanta KS, et al. Mutant IDH inhibits HNF-4a to block hepatocyte differentiation and promote biliary cancer. Nature. 2014:513(7516):110–114.
   PubMed Web of Science ®Google Scholar
• Jörs S, Jeliazkova P, Ringelhan M, et al. Lineage fate of ductular reactions in liver injury and carcinogenesis. J Clin Invest. 2015;125(6):2445–2457.
   PubMed Web of Science ®Google Scholar
• Zhu L, Finkelstein D, Gao C, et al. Multi-organ mapping of cancer risk. Cell. 2016;166(5):1132–1146.e7.
   Web of Science ®Google Scholar
• Frese KK, Tuveson DA. Maximizing mouse cancer models. Nat Rev Cancer. 2007;7(9):645–658.
   PubMed Web of Science ®Google Scholar
• Zhang J, Jiao J, Cermelli S, et al. miR-21 inhibition reduces liver fibrosis and prevents tumor development by inducing apoptosis of CD24+ progenitor cells. Cancer Res. 2015;75(9):1859–1867.
   PubMed Web of Science ®Google Scholar
• Galicia VA, He L, Dang H, et al. Expansion of hepatic tumor progenitor cells in Pten-null mice requires liver injury and is reversed by loss of AKT2. Gastroenterology. 2010;139(6):2170–2182.
   Web of Science ®Google Scholar
• Morris SM, Carter KT, Baek JY, et al. TGF-beta signaling alters the pattern of liver tumorigenesis induced by Pten inactivation. Oncogene. 2015;34(25):3273–3282.
   Web of Science ®Google Scholar
• Xu X, Kobayashi S, Qiao W, et al. Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest. 2006;116(7):1843–1852.
   PubMed Web of Science ®Google Scholar
• Chen WT, Zhu G, Pfaffenbach K, Kanel G, Stiles B, Lee AS. GRP78 as a regulator of liver steatosis and cancer progression mediated by loss of the tumor suppressor PTEN. Oncogene. 2014;33(42):4997–5005.
   Web of Science ®Google Scholar
• Chen WT, Tseng CC, Pfaffenbach K, et al. Liver-specific knockout of GRP94 in mice disrupts cell adhesion, activates liver progenitor cells, and accelerates liver tumorigenesis. Hepatology. 2014;59(3):947–957.
   Web of Science ®Google Scholar
• Zender S, Nickeleit I, Wuestefeld T, et al. A critical role for notch signaling in the formation of cholangiocellular carcinomas. Cancer Cell. 2013;23(6):784–795.
   PubMed Web of Science ®Google Scholar
• Nishio M, Sugimachi K, Goto H, et al. Dysregulated YAP1/TAZ and TGF-beta signaling mediate hepatocarcinogenesis in Mob1a/1b-deficient mice. Proc Natl Acad Sci U S A. 2016;113(1):E71–E80.
   Web of Science ®Google Scholar
• El Khatib M, Bozko P, Palagani V, Malek NP, Wilkens L, Plentz RR. Activation of Notch signaling is required for cholangiocarcinoma progression and is enhanced by inactivation of p53 in vivo. PLoS One. 2013;8(10):e77433.
   PubMed Web of Science ®Google Scholar
• Morris SM, Baek JY, Koszarek A, Kanngurn S, Knoblaugh SE, Grady WM. Transforming growth factor-beta signaling promotes hepatocarcinogenesis induced by p53 loss. Hepatology. 2012;55(1):121–131.
   Web of Science ®Google Scholar
• Terada M, Horisawa K, Miura S, et al. Kupffer cells induce Notch-mediated hepatocyte conversion in a common mouse model of intrahepatic cholangiocarcinoma. Sci Rep. 2016;6:34691.
   PubMed Web of Science ®Google Scholar
• Marsh V, Davies EJ, Williams GT, Clarke AR. PTEN loss and KRAS activation cooperate in murine biliary tract malignancies. J Pathol. 2013;230(2):165–173.
   Web of Science ®Google Scholar
• Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet. 2001;29(4):418–425.
   Web of Science ®Google Scholar
• Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001;15(24):3243–3248.
   PubMed Web of Science ®Google Scholar
• Yanger K, Zong Y, Maggs LR, et al. Robust cellular reprogramming occurs spontaneously during liver regeneration. Genes Dev. 2013;27(7):719–724.
   PubMed Web of Science ®Google Scholar
• Yanger K, Knigin D, Zong Y, et al. Adult hepatocytes are generated by self-duplication rather than stem cell differentiation. Cell Stem Cell. 2014;15(3):340–349.
   PubMed Web of Science ®Google Scholar
• Font-Burgada J, Shalapour S, Ramaswamy S, et al. Hybrid periportal hepatocytes regenerate the injured liver without giving rise to cancer. Cell. 2015;162(4):766–779.
   PubMed Web of Science ®Google Scholar
• Ikenoue T, Terakado Y, Nakagawa H, et al. A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion. Sci Rep. 2016;6:23899.
   Web of Science ®Google Scholar
• Marquardt JU, Andersen JB, Thorgeirsson SS. Functional and genetic deconstruction of the cellular origin in liver cancer. Nat Rev Cancer. 2015;15(11):653–667.
   Web of Science ®Google Scholar
• Fan B, Malato Y, Calvisi DF, et al. Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest. 2012;122(8):2911–2915.
   PubMed Web of Science ®Google Scholar
• Chan-on W, Nairismägi M-L, Ong CK, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet. 2013;45(12):1474–1478.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47(9):1003–1010.
   PubMed Web of Science ®Google Scholar
• Tschaharganeh DF, Xue W, Calvisi DF, et al. p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. Cell. 2014;158(3):579–592.
   Web of Science ®Google Scholar
• O’Dell MR, Huang JL, Whitney-Miller CL, et al. Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res. 2012;72(6):1557–1567.
   PubMed Web of Science ®Google Scholar
• Boulter L, Guest RV, Kendall TJ, et al. WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited. J Clin Invest. 2015;125(3):1269–1285.
   PubMed Web of Science ®Google Scholar
• Guest RV, Boulter L, Dwyer BJ, et al. Notch3 drives development and progression of cholangiocarcinoma. Proc Natl Acad Sci U S A. 2016; 113(43):12250–12255.
   PubMed Web of Science ®Google Scholar
• Winograd R, Byrne KT, Evans RA, et al. Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. Cancer Immunol Res. 2015;3:399–411.
   PubMed Web of Science ®Google Scholar
• Saborowski A, Saborowski M, Davare MA, Druker BJ, Klimstra DS, Lowe SW. Mouse model of intrahepatic cholangiocarcinoma validates FIG–ROS as a potent fusion oncogene and therapeutic target. Proc Natl Acad Sci U S A. 2013;110(48):19513–19518.
   PubMed Web of Science ®Google Scholar
• Saborowski M, Saborowski A, Morris JP, et al. A modular and flexible ESC-based mouse model of pancreatic cancer. Genes Dev. 2014;28(1):85–97.
   PubMed Web of Science ®Google Scholar
• Ju HL, Han KH, Lee JD, Ro SW. Transgenic mouse models generated by hydrodynamic transfection for genetic studies of liver cancer and preclinical testing of anti-cancer therapy. Int J Cancer. 2016;138(7):1601–1608.
   Web of Science ®Google Scholar
• Ding N, Che L, Li XL, et al. Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice. World J Gastroenterol. 2016;22(6):2071–2080.
   Web of Science ®Google Scholar
• Che L, Fan B, Pilo MG, et al. Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans. Oncogenesis. 2016;5(12):e274.
   Google Scholar
• Ho C, Wang C, Mattu S, et al. AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways. Hepatology. 2012;55(3):833–845.
   PubMed Web of Science ®Google Scholar
• Huntzicker EG, Hotzel K, Choy L, et al. Differential effects of targeting Notch receptors in a mouse model of liver cancer. Hepatology. 2015;61(3):942–952.
   PubMed Web of Science ®Google Scholar
• Fan L, Xu C, Wang C, et al. Bmi1 is required for hepatic progenitor cell expansion and liver tumor development. PLoS One. 2012;7(9):e46472.
   Web of Science ®Google Scholar
• Yamada D, Rizvi S, Razumilava N, et al. IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. Hepatology. 2015;61(5):1627–1642.
   PubMed Web of Science ®Google Scholar
• Li X, Tao J, Cigliano A, et al. Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver. Oncotarget. 2015;6(12):10102–10115.
   Google Scholar
• Rizvi S, Yamada D, Hirsova P, et al. A hippo and fibroblast growth factor receptor autocrine pathway in cholangiocarcinoma. J Biol Chem. 2016;291(15):8031–8047.
   PubMed Web of Science ®Google Scholar
• O’Donnell KA, Keng VW, York B, et al. A Sleeping Beauty mutagenesis screen reveals a tumor suppressor role for Ncoa2/Src-2 in liver cancer. Proc Natl Acad Sci U S A. 2012;109(21):E1377–E1386.
   Web of Science ®Google Scholar
• Keng VW, Villanueva A, Chiang DY, et al. A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol. 2009;27(3):264–274.
   Web of Science ®Google Scholar
• Sanchez-Rivera FJ, Jacks T. Applications of the CRISPR-Cas9 system in cancer biology. Nat Rev Cancer. 2015;15(7):387–395.
   PubMed Web of Science ®Google Scholar
• Xue W, Chen S, Yin H, et al. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature. 2014;514(7522):380–384.
   PubMed Web of Science ®Google Scholar
• Weber J, Ollinger R, Friedrich M, et al. CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice. Proc Natl Acad Sci U S A. 2015;112(45):13982–13987.
   PubMed Web of Science ®Google Scholar
• Yin H, Xue W, Chen S, et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol. 2014;32(6):551–553.
   PubMed Web of Science ®Google Scholar
• Aparicio S, Hidalgo M, Kung AL. Examining the utility of patient-derived xenograft mouse models. Nat Rev Cancer. 2015;15(5):311–316.
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Amant F, Biankin AV, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4(9):998–1013.
   PubMed Web of Science ®Google Scholar
• Fichtner I, Slisow W, Gill J, et al. Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer. 2004;40(2):298–307.
   Web of Science ®Google Scholar
• Fichtner I, Rolff J, Soong R, et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res. 2008;14(20):6456–6468.
   PubMed Web of Science ®Google Scholar
• Nemati F, Bras-Goncalves R, Fontaine JJ, et al. Preclinical assessment of cisplatin-based therapy versus docetaxel-based therapy on a panel of human non-small-cell lung cancer xenografts. Anticancer Drugs. 2009;20(10):932–940.
   Web of Science ®Google Scholar
• Cavalloni G, Peraldo-Neia C, Sassi F, et al. Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation. BMC Cancer. 2016;16:90.
   Web of Science ®Google Scholar
• Saha SK, Gordan JD, Kleinstiver BP, et al. Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma. Cancer Discov. 2016;6(7):727–739.
   PubMed Web of Science ®Google Scholar
• Baker LA, Tiriac H, Clevers H, Tuveson DA. Modeling pancreatic cancer with organoids. Trends Cancer. 2016;2(4):176–190.
   PubMed Web of Science ®Google Scholar
• Boj SF, Hwang CI, Baker LA, et al. Organoid models of human and mouse ductal pancreatic cancer. Cell. 2015;160(1–2):324–338.
   PubMed Web of Science ®Google Scholar
• Huang L, Holtzinger A, Jagan I, et al. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. Nat Med. 2015;21(11):1364–1371.
   PubMed Web of Science ®Google Scholar